Optomed Q2: Initial take – Lower sales and EBIT than expected - Redeye

Redeye notes that Q2 sales and EBIT were lower than anticipated. However, we argue that the upcoming quarterly reports will be of higher importance for the company as they may create a better understanding of the demand for Optomed’s US business model, which is a significant part of our valuation. Furthermore, we will release a research update where we will dig deeper into the report.

Länk till analysen i sin helhet: https://www.redeye.se/research/1027782/optomed-q2-initial-take-lower-sales-and-ebit-than-expected?utm_source=finwire&utm_medium=RSS